Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator

You may also be interested in...



PTC’s Cystic Fibrosis Drug Performs Well In Phase II

Foundation says drug is exception to rule, and fronts more funding.

Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease

10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.

Topics

UsernamePublicRestriction

Register

PS003976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel